Celsion (CLSN) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Celsion (NASDAQ:CLSN) from a hold rating to a sell rating in a report published on Wednesday.

According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “

Several other equities research analysts also recently weighed in on the stock. ValuEngine downgraded shares of Celsion from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Brookline Capital Management reissued a buy rating on shares of Celsion in a research report on Tuesday, November 20th. Finally, Oppenheimer set a $9.00 target price on shares of Celsion and gave the stock a buy rating in a research report on Thursday, November 15th.



Celsion stock remained flat at $$1.81 during midday trading on Wednesday. 49,274 shares of the company traded hands, compared to its average volume of 88,463. Celsion has a 12-month low of $1.35 and a 12-month high of $3.48. The stock has a market cap of $34.56 million, a P/E ratio of -0.76 and a beta of 1.60. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.84 and a quick ratio of 3.84.

Celsion (NASDAQ:CLSN) last released its earnings results on Thursday, November 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.04). The company had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative return on equity of 104.30% and a negative net margin of 4,282.33%. As a group, sell-side analysts predict that Celsion will post -1.34 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in shares of Celsion by 72.3% in the 2nd quarter. BlackRock Inc. now owns 114,844 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 48,194 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Celsion by 40.9% in the 3rd quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the period. Finally, Vanguard Group Inc boosted its holdings in shares of Celsion by 40.9% in the 3rd quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock valued at $2,050,000 after buying an additional 214,829 shares during the period. 6.29% of the stock is owned by institutional investors.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply